Pasithea Therapeutics Corp. KTTA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.55% | 29.59% | 23.55% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.89% | 28.80% | 17.14% | -- | -- |
| Operating Income | -43.89% | -28.80% | -17.14% | -- | -- |
| Income Before Tax | -58.22% | -45.03% | -46.91% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.22% | -45.03% | -46.91% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.22% | -45.03% | -46.91% | -- | -- |
| EBIT | -43.89% | -28.80% | -17.14% | -- | -- |
| EBITDA | -46.01% | -30.15% | -17.86% | -- | -- |
| EPS Basic | 80.69% | 81.57% | 72.92% | -- | -- |
| Normalized Basic EPS | 84.94% | 84.61% | 75.47% | -- | -- |
| EPS Diluted | 80.69% | 81.57% | 72.92% | -- | -- |
| Normalized Diluted EPS | 84.94% | 84.61% | 75.47% | -- | -- |
| Average Basic Shares Outstanding | 655.12% | 803.90% | 540.17% | -- | -- |
| Average Diluted Shares Outstanding | 655.12% | 803.90% | 540.17% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |